The collaboration with QUT will see 1600 Queensland cancer patients, over the next 18 months, receive free personalised tumour analyses with the potential to be identified for new treatment trials. PrOSPeCT's mission is to transform cancer care in Australia by establishing a sustainable network for precision genomic testing and clinical trials. This network will enable cancer patients to access the latest therapies with the potential to reduce treatment and testing costs. The ATGC is a major contributor of genomic reports to the program. ATGC Deputy Director of Genomics Associate Professor Paul Leo said precision medicine allowed individual patients to be connected to treatments tailored to their specific cancer based on genomic testing. "This strategic collaboration with Omico has the potential to transform the landscape of cancer care in Queensland, bringing us closer to our objective of providing precision medicine to every cancer patient in Queensland," Associate Professor Leo said.